Is the phosphorus-lowering benefit of patiromer compelling enough to switch a patient with chronic hyperkalemia and hyperphosphatemia from sodium zirconium cyclosilicate to patiromer?  

There are some evidence suggesting that the calcium that is released when patiromer binds to potassium can bind intestinal phosphorus, thereby lowering the serum phosphorus. However, these studies were post hoc analyses, and there were no placebo comparison. Therefore, future controlled studies are ...

I don't think so but I think Patiromer is a better agent anyway as it does not have sodium in it. Patients with CKD and especially dialysis patients are often volume overloaded. It definitely makes sense to use an agent that does not have sodium in it.